Dino's Bar & Grill Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Dino's Bar & Grill

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Goose94 who wrote (7132)	6/18/2014 7:36:06 AM
From: Goose94	Read Replies (1) of 203399

Theralase Technologies (TLT-V) June 18, '14 has executed an agreement with the University of Toledo to conduct preclinical research into the safety and effectiveness of Theralase's photodynamic compounds in the destruction of bladder cancer in a rat model. The study is entitled, "The use of novel Photo Dynamic Therapy (PDT) in a rat bladder tumor model." The first phase of this preclinical study will be to optimize the effectiveness of various Theralase PDCs in the destruction of rat bladder tumor cells (AY-27) using various PDC concentrations and laser light doses.The second phase will be to complete two in vivo rat tumor model studies. The first set of experiments will examine PDC uptake and distribution in rat bladder tumors. The second set of experiments will focus on destroying rat bladder cancer safely and effectively through the instillation of PDCs into rat bladders exhibiting cancerous tumours and then light activating them. The outcome of these experiments will provide independent confirmation and optimization of the lead PDC selected for bladder cancer destruction and prove the safety and efficacy of the Theralase lead PDC in the destruction of bladder cancer in a live animal model. Dr. Arkady Mandel, Chief Scientific Officer at Theralase Inc. stated, "I am interested in reviewing the results of an independent confirmation and optimization of the safety and efficacy of the Theralase PDC in destroying bladder cancer in an orthotopic (occurring at the normal place) rat model. The University of Toledo is a great choice for this research, as their group is well known for expertise in the urological applications of PDT. The results of this preclinical research will allow the Company to progress to Good Manufacturing Practice (GMP) manufacture of the lead PDC. We are delighted to have the experience and knowledge of the University of Toledo on board to execute this pivotal preclinical research, as they will be instrumental in helping us prove the destruction of rat bladder cancer with PDCs in 2014, preparing us for clinical application in 2015. "Roger Dumoulin-White, President and CEO of Theralase stated that, "Theralase is delighted that we have executed a research agreement with the University of Toledo. Completion of this work is pivotal for Theralase to independently validate and optimize our research findings in the PDT destruction of bladder cancer. Results of the University of Toledo's work will determine the uptake and distribution of the PDCs into bladder cancer tumors versus healthy bladder and the amount of PDCs required to safely and effectively destroy bladder cancer in a live animal model. This data will be instrumental in helping to determine the proper amount of PDC required for human application. I look forward to reporting on the results of this exciting research later this year."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next